Jun 02, 2022 / 05:00PM GMT
Boris Peaker - Cowen and Company, LLC - Analyst
Thank you for joining us at the Third Annual Cowen Oncology Innovation Summit. And the next company with us is Mersana Therapeutics. And it's my pleasure to host, Brian DeSchuytner, who is the Senior Vice President and Chief Financial Officer; and Tim Lowinger, who is the Chief Science and Technology Officer. Thanks, guys, for joining us today.
Brian DeSchuytner - Mersana Therapeutics, Inc. - SVP & CFO
Great. Thank you, Boris. Maybe we'll make a quick opening statement to give an overview of Mersana. I'll begin and I'll make some forward-looking statements in the process of that.
So Mersana is a leader in ADC innovation. Our strategic vision is to build on this leadership from discovery to commercialization. ADCs are now validated modality, yet we believe that the field has yet to realize its full potential because the platform innovation has been limited to date. We've actually developed three proprietary platforms that we believe address key limitations of the first-generation approaches and at the
Mersana Therapeutics Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript
Jun 02, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers